# Hospital Universitario 12 De Octubre

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/hospital-universitario-12-de-octubre/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 55 |
| Citations | 972,679 |
| City | Madrid |
| Country | ES |
| Description | Hospital Universitario 12 De Octubre is a research organisation in Madrid, ES. OpenAlex records 21,936 works and 972,679 citations for it. 6,704 researchers list it as their most recent affiliation. |
| Homepage | https://www.comunidad.madrid/hospital/12octubre/ |
| OpenAlex ID | https://openalex.org/I4210101691 |
| Researchers | 6,704 |
| ROR ID | https://ror.org/00qyh5r35 |
| Type | healthcare |
| Works | 21,936 |

## University papers

Showing 12 of 52.

- [Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-advanced-squamous-cell-non-small-cell-lung-cancer/)
- [Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial](https://scholariq.org/papers/erlotinib-versus-standard-chemotherapy-as-first-line-treatment-for-european/)
- [Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer](https://scholariq.org/papers/durvalumab-after-chemoradiotherapy-in-stage-iii-non-small-cell-lung-cancer/)
- [2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines](https://scholariq.org/papers/2019-acc-aha-guideline-on-the-primary-prevention-of-cardiovascular-disease-a/)
- [2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines](https://scholariq.org/papers/2019-acc-aha-guideline-on-the-primary-prevention-of-cardiovascular-disease/)
- [Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-for-squamous-non-small-cell-lung-cancer/)
- [Lung cancer: current therapies and new targeted treatments](https://scholariq.org/papers/lung-cancer-current-therapies-and-new-targeted-treatments/)
- [Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden](https://scholariq.org/papers/nivolumab-plus-ipilimumab-in-lung-cancer-with-a-high-tumor-mutational-burden/)
- [Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-plus-ipilimumab-in-advanced-non-small-cell-lung-cancer/)
- [Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC](https://scholariq.org/papers/overall-survival-with-durvalumab-after-chemoradiotherapy-in-stage-iii-nsclc/)
- [First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer](https://scholariq.org/papers/first-line-nivolumab-in-stage-iv-or-recurrent-non-small-cell-lung-cancer/)
- [Olaparib for Metastatic Castration-Resistant Prostate Cancer](https://scholariq.org/papers/olaparib-for-metastatic-castration-resistant-prostate-cancer/)

## University researchers

- [N. Fernández](https://scholariq.org/researchers/n-fernandez/)

## University top topics

Showing 8 of 25.

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Renal Transplantation Outcomes and Treatments](https://scholariq.org/topics/renal-transplantation-outcomes-and-treatments/)
- [COVID-19 Clinical Research Studies](https://scholariq.org/topics/covid-19-clinical-research-studies/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.